Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, Surita Dalal et al.|New England Journal of Medicine|2023Cited by 155
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapyToby A. Eyre, Graham P. Collins, Harriet S. Walter et al.|Haematologica|2018Cited by 137
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysisToby A. Eyre, Amy A. Kirkwood, Satyen H. Gohil et al.|British Journal of Haematology|2019Cited by 79